International Journal of Hematology and Oncology
2023, Vol 33, Num 4 Page(s): 106-114
| Back | Table of Contents | PDF | Mail to Author | |
Clinical, Laboratory and Radiologic Course and Prognosis of COVID-19 in Cancer Patients and Comparison with General Population: A Single-Center Experience
Erkan ERDUR1, Ozgen Ahmet YILDIRIM1, Kerem POYRAZ1, Canan CAN3, Halil KOMEK3
1Gazi Yasargil Training and Research Hospital, Department of Internal Medicine, Division of Medical Oncology, Diyarbakir, TURKEY
2Gazi Yasargil Training and Research Hospital Department of Radiation Oncology, Diyarbakir, TURKEY
3Gazi Yasargil Training and Research Hospital, Department of Nuclear Medicine, Diyarbakir, TURKEY
Keywords: COVID19, Cancer Patients , Retrospective case study
In this study, we aimed to investigate the clinical findings and follow-up data of patients with COVID-19 and had a history of cancer, and compare these data with other COVID-19 patients. We included 2349 COVID-19 inpatients between March 2020 and July 2020. 82 of these patients were found to have a cancer diagnosis (Group 1). Patients undergoing chemotherapy were assigned to group 1A, patients receiving non-chemotherapy treatment were assigned to group 1B, cancer patients without any treatment to group 1C and non-cancer patients to group 2. These groups were compared in terms of basic demographic characteristics, symptoms, comorbidities, laboratory and imaging findings, intensive care unit (ICU) admission rate and death. The median age of the patients in group 1 was statistically higher than group 2 (61 and 52, p< 0.001). The most common cancer diagnosis was breast cancer (n= 16, 19.5%). Inflammatory parameters such as CRP and D-dimer were found to be higher in patients in group 1 than group 2 (p= 0.005 and p= 0.003, respectively). The mortality rate of the patients in group 1 was 15.8%, while the mortality rate in group 2 was 5.1% and this was statistically significantly higher (p< 0.001). Being in group 1 and group 1A were determined as the predictive parameters for death (r= 0.087, p< 0.001 and r: 0.254 , p= 0.021 respectively). Our data suggests that history of cancer and active chemotherapy treatment are independent prognostic factors for severe disease and mortality in COVID-19.
Erkan ERDUR1, Ozgen Ahmet YILDIRIM1, Kerem POYRAZ1, Canan CAN3, Halil KOMEK3
1Gazi Yasargil Training and Research Hospital, Department of Internal Medicine, Division of Medical Oncology, Diyarbakir, TURKEY
2Gazi Yasargil Training and Research Hospital Department of Radiation Oncology, Diyarbakir, TURKEY
3Gazi Yasargil Training and Research Hospital, Department of Nuclear Medicine, Diyarbakir, TURKEY
Keywords: COVID19, Cancer Patients , Retrospective case study
In this study, we aimed to investigate the clinical findings and follow-up data of patients with COVID-19 and had a history of cancer, and compare these data with other COVID-19 patients. We included 2349 COVID-19 inpatients between March 2020 and July 2020. 82 of these patients were found to have a cancer diagnosis (Group 1). Patients undergoing chemotherapy were assigned to group 1A, patients receiving non-chemotherapy treatment were assigned to group 1B, cancer patients without any treatment to group 1C and non-cancer patients to group 2. These groups were compared in terms of basic demographic characteristics, symptoms, comorbidities, laboratory and imaging findings, intensive care unit (ICU) admission rate and death. The median age of the patients in group 1 was statistically higher than group 2 (61 and 52, p< 0.001). The most common cancer diagnosis was breast cancer (n= 16, 19.5%). Inflammatory parameters such as CRP and D-dimer were found to be higher in patients in group 1 than group 2 (p= 0.005 and p= 0.003, respectively). The mortality rate of the patients in group 1 was 15.8%, while the mortality rate in group 2 was 5.1% and this was statistically significantly higher (p< 0.001). Being in group 1 and group 1A were determined as the predictive parameters for death (r= 0.087, p< 0.001 and r: 0.254 , p= 0.021 respectively). Our data suggests that history of cancer and active chemotherapy treatment are independent prognostic factors for severe disease and mortality in COVID-19.
| Back | Table of Contents | PDF | Mail to Author | |